Cartesian Therapeutics (FRA:1S70) Cyclically Adjusted Book per Share: €20.35 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1S70 Cartesian Therapeutics Inc FRA:1S70
27 GF Score
Price €6.60
GF Value €0.23
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cartesian Therapeutics Cyclically Adjusted Book per Share?

Cartesian Therapeutics FRA:1S70 +2.33% 27 Cyclically Adjusted Book per Share is €20.35 as of Mar. 2026. GuruFocus rates FRA:1S70 with a GF Score™ of 27/100 and a GF Value™ of €0.23 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Cartesian Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €-4.488. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €20.35 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Cartesian Therapeutics's average Cyclically Adjusted Book Growth Rate was 30.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-26), Cartesian Therapeutics's current stock price is €6.60. Cartesian Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €20.35. Cartesian Therapeutics's Cyclically Adjusted PB Ratio of today is 0.32.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Cartesian Therapeutics was 1.90. The lowest was 0.24. And the median was 0.53.


Cartesian Therapeutics  (FRA:1S70) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cartesian Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=6.60/20.35
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Cartesian Therapeutics was 1.90. The lowest was 0.24. And the median was 0.53.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Cartesian Therapeutics Cyclically Adjusted Book per Share Related Terms


Cartesian Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Cartesian Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cartesian Therapeutics Cyclically Adjusted Book per Share Chart

Cartesian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 19.10 17.92

Cartesian Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.67 15.06 14.04 17.92 20.35

FRA:1S70 vs LYEL, ALXO, ARMP: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Cartesian Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cartesian Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cartesian Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:1S70
27GF Score
Cartesian Therapeutics Inc FRA:1S70
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cartesian Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cartesian Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-4.488/330.2130*330.2130
=-4.488

Current CPI (Mar. 2026) = 330.2130.

Cartesian Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 102.531 241.018 140.475
201609 96.221 241.428 131.606
201612 84.714 241.432 115.866
201703 62.167 243.801 84.201
201706 94.669 244.955 127.619
201709 74.083 246.819 99.114
201712 58.769 246.524 78.720
201803 45.266 249.554 59.897
201806 27.802 251.989 36.432
201809 11.457 252.439 14.987
201812 -6.358 251.233 -8.357
201903 8.784 254.202 11.411
201906 0.033 256.143 0.043
201909 -2.777 256.759 -3.571
201912 2.626 256.974 3.374
202003 -2.734 258.115 -3.498
202006 -3.447 257.797 -4.415
202009 -1.753 260.280 -2.224
202012 -4.109 260.474 -5.209
202103 -4.365 264.877 -5.442
202106 -0.913 271.696 -1.110
202109 -4.137 274.310 -4.980
202112 4.836 278.802 5.728
202203 12.213 287.504 14.027
202206 16.654 296.311 18.559
202209 16.812 296.808 18.704
202212 17.364 296.797 19.319
202303 13.621 301.836 14.902
202306 11.812 305.109 12.784
202309 10.951 307.789 11.749
202312 -74.778 306.746 -80.499
202403 -19.481 312.332 -20.596
202406 -5.290 314.175 -5.560
202409 0.028 315.301 0.029
202412 -0.252 315.605 -0.264
202503 -0.777 319.799 -0.802
202506 -0.084 322.561 -0.086
202509 -1.174 324.800 -1.194
202512 -4.145 324.054 -4.224
202603 -4.488 330.213 -4.488

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €20.35 mean?
Cartesian Therapeutics (FRA:1S70) has a Cyclically Adjusted Book per Share of €20.35 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Cartesian Therapeutics and its competitors.
Is Cartesian Therapeutics' Cyclically Adjusted Book per Share too high?
Cartesian Therapeutics' current Cyclically Adjusted Book per Share is €20.35. Overall, Cartesian Therapeutics has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cartesian Therapeutics' Cyclically Adjusted Book per Share compare to LYEL and ALXO?
Cartesian Therapeutics' Cyclically Adjusted Book per Share of €20.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Cartesian Therapeutics and its competitors. Cartesian Therapeutics's current Cyclically Adjusted Book per Share is €20.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cartesian Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cartesian Therapeutics (FRA:1S70) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.23, compared to a current price of €6.60 — trading 2769.6% above its estimated fair value. The current Cyclically Adjusted Book per Share is €20.35. Cartesian Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Cartesian Therapeutics (FRA:1S70), the current Cyclically Adjusted Book per Share is €20.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cartesian Therapeutics (FRA:1S70) Overvalued in 2026?

Based on GuruFocus' analysis, Cartesian Therapeutics stock appears to be overvalued. The current stock price of €6.60 is trading 2769.6% above its estimated GF Value™ of €0.23. GuruFocus considers Cartesian Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:1S70:

  • Cyclically Adjusted Book per Share: €20.35
  • GF Value™: €0.23 vs. price of €6.60 (2769.6% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the FRA:1S70 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cartesian Therapeutics Business Description

Other Exchanges RNAC:USA
Address 7495 New Horizon Way, Frederick, MD, USA, 21703
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
27GF Score

Get the complete analysis for FRA:1S70

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price
€0.23
GF Value